Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Xintela signs agreement with CRO for phase I/II study

Biopharma company Xintela continues to take important steps towards its first clinical trial with the drug candidate XSTEM-OA. This spring, the company was granted permission to produce cell therapy products in its own GMP facility and has now signed an agreement with the Australian CRO GreenLight Clinical to conduct the first clinical trial in humans with the candidate.Read the full interview with Evy Lundgren-Åkerlund at biostock.se:https://www.biostock.se/en/xintela-signs-agreement-with-cro-for-phase-i-ii-study/This is a press release from BioStock - Connecting Innovation & Capital.

Interim Report Q2 2021 - Ayima Group AB

Q2 Apr - Jun 2021 · Total Revenue amounted to 40.5 MSEK (27.8), an increase of 46% from the corresponding period in 2020 · Gross Profit amounted to 20.4 MSEK (18.3), an increase of 11% from the corresponding period in 2020 · Operating costs amounted to 15.7 MSEK (16.6), a reduction of 5% from the corresponding period last year · A positive EBITDA result of 4.7 MSEK (1.8), a 162% increase from the corresponding period in 2020 · EBITDA margin increased to 11% (6%) · Net Profit after tax for the period was 1.6 MSEK (-1.4), an increase of 3.0 MSEK from the corresponding

Storytel appoints Alexis Gresoviac Head of International Operations

Storytel today announced that Alexis Gresoviac is assuming the newly created position of Head of International Operations in the company’s commercial organisation. In his new role, Alexis will be a key player in Storytel’s business development and trajectory of global expansion. Alexis Gresoviac comes from a solid and entrepreneurial career in executive positions in the international gaming industry.“I am very happy to welcome Alexis to Storytel’s commercial team. His strategic mindset, end-user focus and operational excellence in leading truly innovative teams, makes him a perfect fit for

Dutch pioneer in digital pathology renews trust in Sectra with long-term contract

Linköping, Sweden and Almere, the Netherlands – August 12, 2021 – University Medical Center (UMC) Utrecht in the Netherlands has signed a 10-year renewal contract for digital pathology with international medical imaging IT and cybersecurity company Sectra  (STO: SECT B). In 2016, UMC Utrecht was among the first in the world to start digitally reviewing tissue sections for primary diagnostics and the renewal represents a continued joint commitment to driving innovation within digital pathology for the benefit of patients.“UMC Utrecht has always had the ambition to be

Interim report January – June 2021

Press release: Uppsala, August 12, 2021. Pharmacolog i Uppsala AB’s (publ) interim report for the period January – June is now available on the company’s webbsite http://www.pharmacolog.com (Swedish only)Andra kvartalet 1 april – 30 juni 2021 · Koncernens nettoomsättning för perioden uppgick till 939 (568) KSEK. · Rörelseresultatet för koncernen för perioden uppgick till -4 786 (-3 035) KSEK. · Nettoresultat per aktie före och efter utspädning var för perioden -0,38 (-0,31) SEK. Halvåret 1 januari – 30 juni 2021 · Koncernens nettoomsättning för perioden uppgick till 3 402

XMReality AB (publ) Interim report, April – June 2021

The Annual Recurring Revenue (ARR) increased by 23 percent compared to last year’s quarter. The corresponding increase in Net Sales and Order Intake were 2 percent.The quarter April – June 2021 · Net sales amounted to SEK 5,654 thousand (5,549) · Costs totaled SEK –13,994 thousand (-13,302) · The operating loss before appropriations was SEK -7,749 thousand (-7,159) · Cash flow for the period was SEK -6,198 thousand (-11,866) and equity/assets ratio at the end of the period was 79.9 (71.5) percent The growth in Net Sales was 2 percent. The Annual Recurring Revenue (ARR) rose

Bioservo Technologies AB Interim Report January – June 2021

Second quarter in figures · Net sales of SEK 1.0 M (4.8) · EBITDA of SEK -9.6 M (-3.8) · EBIT of SEK –10.9 M (-4.8) · Earnings for the period amounted to SEK -10.9 M (-4.8) · Earnings per share before and after dilution amounted to SEK -0.69 (-0.34) · Cash flow from operating activities for the period amounted to SEK -10.8 M (-6.0) First half-year in figures · Net sales of SEK 2.5 M (7.8) · EBITDA of SEK -17.4 M (-10.4) · EBIT of SEK -19.9 M (-12.4) · Earnings for the period was SEK -19.9 M (-12.4) · Earnings per share before and after dilution

INTERIM REPORT JANUARY–JUNE 2021

(Interim report January - June 2021 is distributed as an appendix to this press release)   APRIL–JUNE 2021 · Net sales amounted to MSEK 341.2 (238.3). · Growth was 43% (-4). · EBIT amounted to MSEK 55.1 (30.3). · EBIT margin amounted to 16.1% (12.7). · Net income was MSEK 42.6 (18.1). · Earnings per share amounted to SEK 0.85 (0.36).  CEO PATRIK ANDERSSON:CONTINUED STRONG GROWTH WITH A HIGH EBIT MARGIN GARO is developing positively. Net sales rose 43% and amounted to MSEK 341.2. EBIT for the quarter rose 82% to MSEK 55.1 and the EBIT margin was 16.1%,

Invitation to Q2 Earnings Teleconference

Karnov Group (Nasdaq: KAR) will publish its financial report for the second quarter and first six months 2021 on 26 August at around 8.00 CEST and Management will host a webcasted telephone conference the same day at 10.00 a.m. CEST.Karnov Group’s half-year report for the period January – June 2021 will be published on Thursday 26 August 2021 at around 8.00 a.m. CEST. A webcasted telephone conference will be held at 10.00 a.m. CEST the same day, where CEO Pontus Bodelsson and CFO Dora Brink Clausen will present the report and answer questions. You can follow the presentation via webcast

DanCann Pharma A/S has reached a historic milestone with the first ever cannabis batch in BIOTECH PHARM1

COPENHAGEN, Denmark, 12 August 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby announce, that the ambitious pharma company has just completed its first successful production run of biomaterial a few weeks after the Company carried out a directed issue of shares and at the same time received loan capital of a double-digit DKK million amount.In April, DanCann Pharma's production facilities BIOTECH PHARM1 were fully established and in June, the company activated the first cultivation activities in the new facility following a prior selection of genetics. After

Norway Royal Salmon ASA (NRS): Statement regarding mandatory offer from NTS ASA

The board of directors of Norway Royal Salmon ASA ("NRS") notes the announcement from NTS ASA that it increases the offer price under its mandatory offer for NRS to NOK 240 and extends the acceptance period until 26 August 2021. The board of directors will assess the revised offer together with its advisers and make a statement with respect to this offer in due course. The evaluation of strategic options announced on 21 July 2021 will continue. Shareholders are encouraged to in any event refrain from accepting the revised offer until the very end of the extended acceptance period (26 August

Aker Offshore Wind and Mainstream Renewable Power Selected as Preferred Bidder to Partner Together in Floating Offshore Wind Project in Japan

Aker Offshore Wind and global wind and solar company, Mainstream Renewable Power(“Mainstream”) have together been selected as the preferred bidder to acquire aninitial 50 percent stake in Progression Energy’s 800MW floating offshore windproject in Japan. The project is a well-formed early-stage development asset.The two companies will now enter into exclusive negotiations with ProgressionEnergy with a view to establishing a special purpose vehicle (“SPV”) in thecoming weeks, to continue collectively developing the project. As a consortium,the three companies bring together

HALF-YEAR REPORT FOR THE FIRST HALF OF 2021

Second quarter 2021     · Net sales rose by 26% to SEK 19,535 (15,490) thousand. Growth is 37%, adjusted for currency effects. · Gross profit rose by 32% to SEK 17,365 (13,146) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 2,793 (loss: 38) thousand. · Operating profit improved by SEK 2,641 thousand and totaled SEK 1,350 (loss: 1,291) thousand. · Comprehensive income for the period improved by SEK 4,156 thousand and totaled SEK 1,033 (loss: 3,123) thousand. · Comprehensive income per share, basic and diluted, totaled SEK 0.01 (-0.02).

Terveystalo to become a manufacturer of software-based medical devices

Terveystalo press release 12 August 2021 Terveystalo has been awarded the ISO 13485 quality system certificate as the first health service provider in Finland. With the certification, Terveystalo will become a manufacturer, distributor, seller and marketer of software-based medical devices. “Medical science guides all of our operations and we are now at the forefront of software development, which is driven by medicine. For us, the certification is a strategic capability that enables the development of intelligent software for healthcare. With even smarter software, we can, among

Acroud publishes interim report Apr-Jun 2021: Sequential growth and strong operational cash flow

Second Quarter 2021 · Revenue amounted to EUR 6 200 (3 567) thousand, corresponding to a growth of 74% (2%) and an organic growth of -25% (2%). · EBITDA amounted to EUR 1 159 (1 499) thousand. Adjusted EBITDA (before items affecting comparability related to acquisitions, reorganization and new share issues) was EUR 1 500 (2 058) thousand. · Profit after tax was EUR -267 (-1 144) thousand. Adjusted profit after tax (before items affecting comparability and currency effects) was EUR 292 (1 297) thousand. · Earnings per share after dilution amounted to EUR -0.002 (-0.015).

From pushcarts to MICHELIN stars, Phuket street food still shines

Street food is undoubtedly one of the most familiar staples of Thai culture. The varieties of street food vary by region around the country, giving visitors endless options to choose from as they travel.   Experiencing street food in Thailand is a given for any trip to the Kingdom. Travelers and residents alike have no shortage of choice when buying fresh, made-to-order Thai food straight from the source. Having many hot off-the-grill options makes enjoying street food the ideal format for savouring many of the dishes that are a fundamental part of the Thai food culture. From

Olvi Group’s Half-Year Report, 1 January to 30 June 2021 (6 Months)

OLVI PLC                             Half-Year Report 12 August 2021 at 9:00 am Olvi Group’s Half-Year Report, 1 January to 30 June 2021 (6 Months) Half-year report in brief Olvi Group’s business development continued on a strong track. Sales volume, net sales, operating profit and net profit all showed good growth on the previous year, and the period under review was the best half-year in Olvi’s history. The Group’s financial standing remains good. Near-term outlook (updated) Olvi’s operating profit for fiscal year 2021 is expected to remain on the previous year’s good level

Fuud-owned brand Beijing8 is centrally listed at ICA

STOCKHOLM, 12 Aug, 2021 08.00 CEST Fuud, which during the first half of 2021 completed several acquisitions within Functional Foods, including Beijing8, continues to grow. The Beijing8 brand will now have a central listing at ICA starting week 39, 2021. Beijing8 is one of Europe's largest brands within the dumpling category and the listing at ICA allows the company to continue to create a nationwide presence at Sweden’s Ica stores.Beijing8 offers slow fast food. We make traditional dumplings, tea and tasty accessories where we combine ancient Chinese food culture with modern values for

Tecnotree Corporation Financial Report for Q2 and Half Year 2021

Tecnotree Corporation Stock Exchange Release 12 Aug 2021 at 9:00 EETSTRONG GROWTH IN REVENUE AND ORDER BOOK CONTINUES [][]Key figures, MEUR 4-6/ 4-6/ 1-6/ 1-6/ 1-12/ 2021 2020 2021 2020 2020Net sales 16,7 14,1 27,9 24,0 52,8Adjusted 7,6 5,8 10,6 8,1 19,3operating result[1]Operating result 7,6 6,3 10,6 7,4 18,6Result before 6,2 5,4 9,1 6,4 15,9taxesAdjusted result 5,3 3,8 7,7 5,5 14,2for the period[2]Result for the 5,3 4,2 7,7 4,8 13,6period Earnings

Oda places order worth €310 000

Norway based company Oda, former Kolonial, who is a leading supplier of online food deliveries has placed another major order with FlexQube. Total order value is approximately €310 000 and will be delivered to a new distribution center currently being built in Finland. The patented concept by FlexQube, where everything is bolted together, makes it possible to deliver the equipment to the new facility unassembled and then have everything assembled onsite at the customer instead. This will drastically reduce the need for transportation, in this case 8 truckloads less in total, and thus

Terveystalo Group Half-Year Report 1 January - 30 June 2021: Strong growth in revenue and profit compared to lockdown-influenced reference period

Terveystalo Plc, Half-Year Report, 12 August 2021 at 9:00 EEST This release is a summary of Terveystalo's Half-Year Report 1 January - 31March 2021. The full release is attached to this stock exchange release and is available on our website at: https://www.terveystalo.com/en/investors/Financial-information/. April–June 2021 in brief · Revenue increased by 31.6 percent year-on-year[1)] to EUR 275.3 (209.2) million. · Adjusted[2)] earnings before interest, taxes, and amortization (EBITA) increased to EUR 29.5 (8.8) million, representing 10.7 (4.2) percent of revenue. ·

Arla Plast AB Interim Report January – June 2021

DEMAND NORMALISED FOR PANDEMIC RELATED BARRIER PRODUCTS BUT STRONG FOR HOME AND GARDENAPRIL – JUNE 2021 · Sales volume amounted to 6,100 tonnes (7,200 tonnes). · Net sales declined by 6% to SEK 246.3 (260.8) million. Organic decline was 7%. · Operating profit declined by 38% to SEK 23.7 (38.5) million and adjusted operating profit by 31% to SEK 26.4 (38.5) million. · The operating margin decreased to 9.6% (14.8%) and the adjusted operating margin to 10.7% (14.8%).  · Profit for the period weakened by 37% to SEK 18.6 (29.2) million. · Earnings per share before dilution

Invitation to earnings call for interim report January-June 2021

On August 18, 08.00 (CEST), the interim report January-June 2021 will be published and in connection with this, an earnings call will be arranged at 14:00 (CEST) the same day. The earnings call will be available afterwards on the company’s website.  Since the company is currently undergoing a name change from CELLINK to BICO, presentation material will be available at both www.cellink.com and www.bico.com. The presentation will be held in English. Date: Wednesday, August 18, 2021. 14:00 (CEST)For audio: +46 8 502 439 36 Conference-ID: 451 928 581#For video: Video link 

Relais Group Plc Half-year financial report January 1–June 30, 2021 (unaudited) – The growth story continues

Relais Group PlcCompany release August 12, 2021, 9 a.m. EET   This release is a summary of Relais Group’s Half-year financial report January–June 2021. The full release is attached to this company release and is available on our website at https://relais.fi/en/investors/. JANUARY-JUNE 2021 IN BRIEF · Net sales totaled EUR 105.8 million (January–June 2020: 59.0), +79.4% change · EBITDA was EUR 13.0 (7.7) million, 12.3% (13.1%) of net sales, +68.9% change · EBITA was EUR 12.2 (7.5) million, 11.5% (12.7%) of net sales, +62.6% change · EBIT was EUR 6.1 (3.7) million, 5.

There are no items matching the current filter
There are no more items matching the current filter
Back to top